Relmada Therapeutics, Inc. (RLMD)
NASDAQ: RLMD · Real-Time Price · USD
7.24
+0.21 (2.99%)
At close: Apr 28, 2026, 4:00 PM EDT
7.50
+0.26 (3.59%)
After-hours: Apr 28, 2026, 7:48 PM EDT
Company Description
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States.
The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity.
The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Relmada Therapeutics, Inc.
| Country | United States |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 17 |
| CEO | Sergio Traversa |
Contact Details
Address: 2222 Ponce de Leon Blvd., Floor 3 Coral Gables, Florida 33134 United States | |
| Phone | 786 629 1376 |
| Website | relmada.com |
Stock Details
| Ticker Symbol | RLMD |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001553643 |
| CUSIP Number | 75955J402 |
| ISIN Number | US75955J4022 |
| Employer ID | 45-5401931 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Sergio Traversa M.B.A., Pharm.D. | Chief Executive Officer and Director |
| Maged S. Shenouda M.B.A., R.Ph. | Chief Financial Officer |
| Paul E. Kelly M.B.A. | Chief Operating Officer and Director |
| Gina DiGuglielmo | Vice President and Head of Clinical Operations |
| Dr. Raj S. Pruthi F.A.C.S., M.D., M.H.A. | Chief Medical Officer of Urology |
| Dr. Andrew Cutler | Senior Clinical Development Advisor |
| Dr. Richard M. Mangano Ph.D. | Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 17, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 9, 2026 | EFFECT | Notice of Effectiveness |
| Apr 9, 2026 | 424B3 | Prospectus |
| Apr 6, 2026 | PRE 14A | Other preliminary proxy statements |
| Apr 3, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Mar 20, 2026 | 8-K | Current Report |
| Mar 19, 2026 | 10-K | Annual Report |
| Mar 9, 2026 | 8-K | Current Report |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |